Últimas noticias sobre Mustang Bio (NASDAQ:MBIO) Bolsa

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio Inc

Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) disclosed several transactions and partnerships at the Baker Hughes <a target="_blank" href="https://www.benzinga.com/quote/BKR" rel="noreferrer noopener">2025 Annual Meeting in Florence</a>.
ExxonMobil Contract: Baker Hughes secured a contract from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) Guyana to supply specialty chemicals and services for the Uaru and Whiptail offshore <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426683/baker-hughes-secures-major-chemicals-award-from-exxonmobil-guyana-for-fpsos" rel="noreferrer noopener">developments in the Stabroek Block</a>.
Uaru and Whiptail are ExxonMobil Guyana&#8217;s fifth and sixth projects, featuring up to 20 drill centers and 92 wells.
Each FPSO will have a capacity of 250,000 barrels per day, raising the country's total production capacity to 1.3 million barrels per day.
The multi-year contract covers topsides, subsea, water injection, and utility chemicals for the Errea Wittu and Jaguar FPSOs, set to begin production in 2026 and 2027, respectively.
Hanwha Partnership: Baker Hughes inked a joint Development and Collaboration Agreement (JDCA) with Hanwha Power Systems and Hanwha Ocean to develop a small-size <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426721/baker-hughes-and-hanwha-announce-partnership-to-develop-small-size-ammonia-turbines" rel="noreferrer noopener">turbine for ammonia applications</a>.
The turbine will combine Baker Hughes&#8217; gas turbine technology with Hanwha&#8217;s ammonia combustion system.
Baker and Hanwha plan to complete full engine testing with ammonia by the end of 2027, after which the ~16MW turbine will be available for commercial orders.
Argent LNG Contract: The company has been chosen by Argent LNG as the liquefaction solution and services provider for its proposed LNG <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43427007/argent-lng-selects-baker-hughes-as-technology-provider-strengthening-project" rel="noreferrer noopener">export facility in Port Fourchon, Louisiana</a>.
Baker Hughes will supply liquefaction technology, power generation equipment, and gas compression systems for the facility, which aims to produce approximately 24 MTPA of LNG.
Last month, Baker Hughes reported fourth-quarter adjusted EPS&nbsp;of $0.70, beating the consensus of $0.63 and sales&nbsp;of $7.36 billion, exceeding <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43356061/baker-hughes-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">the street view of&nbsp;$7.08 billion</a>.
Investors can gain exposure to the stock via iShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>) and&nbsp;VanEck Oil Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>).
Price Action: BKR shares are up 0.39% at $46.36 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43427872" target="_blank" rel="noreferrer noopener">Dow Dips Over 300 Points As Trump Imposes Tariffs On Canada, Mexico, And China: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

News

Contracts

Baker Hughes Lands ExxonMobil Guyana Deal, Partners With Hanwha On Ammonia Turbines

Keybanc analyst Bradley Thomas maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Overweight and raises the price target from $66 to $70.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Tempur Sealy Intl, Raises Price Target to $70

Keybanc analyst Paul Knight maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and raises the price target from $132 to $145.

RVTY

Keybanc Maintains Overweight on Revvity, Raises Price Target to $145

Keybanc analyst Steve Barger maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $375 to $395.

Keybanc Maintains Overweight on RBC Bearings, Raises Price Target to $395

Unusual Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) has announced the signing of a binding agreement to acquire of Aloft Technologies, Inc. (<a href="https://pr.report/6pai">https://www.aloft.ai/</a>), the leading FAA-approved provider of unmanned aerial system (UAS) services to enterprise, public safety, and government customers. The acquisition is almost all in stock, valued at $14.5M.
The proposed acquisition brings together companies that share commitment to strengthening the U.S. drone industry. Aloft Technologies has long been recognized as the leader in the drone fleet and airspace management sector, powering more than 70% of all FAA-approved Low Altitude Authorization and Notification Capability (LAANC) airspace authorizations in the United States. Aloft has provided more than more than 1.6 million authorizations in total, with 400,000 authorizations provided in 2024.
Aloft has been able to leverage the data collected through millions of safe flights and airspace interactions to launch <a href="https://pr.report/6paj">Air Boss</a>, their new real-time UAS air traffic management (UTM) software. With the FAA <a href="https://pr.report/6pak">forecasting</a> more than 3 million drones in the airspace by 2028, outnumbering traditional aircraft more than 10-to-1, the coordination and integration of all aircraft is critical to national security and the national economy.
The closing of the acquisition is contingent on satisfaction of customary closing conditions by the parties including Aloft obtaining stockholder approval, the delivery by Aloft of its audited financials acceptable to Unusual Machines, the receipt of certain third party consents and the holders of no more than 10% of Aloft common stock have asserted appraisal rights.

UMAC

Unusual Machines Enters Into Definite Agreement To Acquire Drone Software Company Aloft Technologies; The Acquisition Is Almost All In Stock, Valued At $14.5M

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $50 to $40.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $40

Buybacks

Axis Capital Enters $200M Stock Repurchase Agreement

LICY

LI-Cycle Further Expands Commercial Footprint In EU With Additional Exclusive Recycling Partnership For Its Germany Spoke

Keybanc analyst Tim Rezvan maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $50 to $37.

Keybanc Maintains Overweight on Murphy Oil, Lowers Price Target to $37

Macro Economic Events

Global

Economics

OPEC+ Discussing Changing List Of Secondary Sources It Uses To Monitor Members' Oil Output; OPEC+ Considers Proposal To Remove U.S. Government's EIA As One Of Its Secondary Sources, Sources Say

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $23 to $28.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $28

Keybanc analyst Aleksey Yefremov maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and raises the price target from $121 to $128.

Keybanc Maintains Overweight on Eastman Chemical, Raises Price Target to $128

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) has no revenues. He added, &#8220;It's obviously just a very big spec. I <a href="https://www.benzinga.com/quote/SMMT">can't go there.&#8221;</a>
However, HC Wainwright &amp; Co. analyst Mitchell Kapoor, on Jan. 21, reiterated Summit Therapeutics with a Buy and maintained a $44 price target.
<h3 class="wp-block-heading">This Financial Company Is &#8216;Good&#8217;</h3>
Cramer said HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) is a &#8220;good&#8221; company, but added that he would recommend Banco Santander, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) if he is going to buy one of those that's a foreign bank.
HSBC, meanwhile, on Jan.6, named Lisa McGeough as President and CEO for the United States.
<h3 class="wp-block-heading">Tech Stocks In Focus</h3>
When asked about Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>), he said, &#8220;I have read so many upgrades of Western Digital that I have to believe the stock is way too cheap.&#8221;
On the earnings front, Western Digital, on Jan. 29, reported better-than-expected second-quarter revenue results.
AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) is a &#8220;cheap&#8221; stock, and it's a &#8220;good one,&#8221; Cramer said. &#8220;That one rocks.&#8221;
AppFolio, on Jan. 30, also reported better-than-expected sales results for its fourth quarter.
The Mad Money host said he doesn't want to sell Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) down here. He added, &#8220;I know that it seems like a tough stock to own. I can't sell at 21 times earnings.&#8221;
However, Deutsche Bank analyst Brad Zelnick, on Jan. 8, downgraded Adobe from Buy to Hold and lowered the price target from $600 to $475.
Price Action:
<ul>
<li>HSBC shares fell 0.5% to settle at $52.43 on Friday.</li>
<li>Summit Therapeutics shares fell 3.9% to close at $21.50 during the session.</li>
<li>Western Digital shares fell 1% to settle at $65.13.</li>
<li>AppFolio shares dipped 7.8% to close at $233.91 on Friday.</li>
<li>Adobe shares fell 1.9% to settle at $437.45.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

ADBE

APPF

HSBC

SMMT

Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'

Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol&#xAE;, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.
Dermytol&#xAE; is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol&#xAE; utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The <a href="https://www.globenewswire.com/Tracker?data=GwtS7MM7faaVuXF50nCiIEqF3YZclunD-W2Oc5djnaJ-5RrV_FkWU1wk8H1HdLecpsBP6LAO4Ulu2toHmYIv0l4gUDm7ZuZbxGlieKMERNfAelXeLjdK926Iw9wNYVLcLx-cgONQPCRwcPM6sjmR-gbN1e2BzjJoBQr-BEkuBWs=">patented</a> formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.
The efficacy of Dermytol&#xAE; as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol&#xAE; was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the <a href="https://www.globenewswire.com/Tracker?data=jb3n_m190i60gacTYqoi8qpzZ5EC-ZzRvxQAiOQ2tZabOxrf6vfaMD71kOJmf6Hi6uCZVofXr0q9dN4KnlYDwghRMo-7SZB81FrhmRg1Tm0=">study</a>, this would make Dermytol&#xAE; a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.

Biotech

General

MGRX

Mangoceuticals Announces Exclusive Distribution Agreement With Propre Energie For Dermytol, Plant-Based Skincare Proven To Address Hyperpigmentation And Acne Scars

RSLS

ReShape Lifesciences Granted International Patent For Diabetes Neuromodulation Technology In Israel; Protection Until 2039, Terms Not Disclosed

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>, EDBLW)), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced the expansion of its existing partnership with Walmart. The Company is adding value size fresh-cut basil to its product assortment at Walmart locations. This strategic addition underscores Edible Garden's ongoing commitment to sustainable farming practices and its dedication to reducing environmental impact through Walmart's Project Gigaton.

EDBL

Edible Garden Announces The Expansion Of Its Existing Partnership With Walmart, Adding Value Size Fresh-Cut Basil To Its Product Assortment At Walmart Locations

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) will be reporting its fourth-quarter earnings on Monday. Wall Street expects 11 cents in EPS and $775.91 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=PLTR" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 393.36%% over the past year, 9.71% YTD.
Let&#8217;s look at what the charts indicate for Palantir stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com//node/43426284">Palantir Technologies Plunges Overnight On Robinhood: Trump Tariff Impact Or Investor Jitters?</a>
<h2 class="wp-block-heading">PLTR Stock Strongly Bullish Ahead Of Q4 Earnings&#8230;</h2>
PLTR stock is in a strongly bullish trend, trading above its five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png" alt="" class="wp-image-762426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
At $81.20, the stock sits comfortably above key moving averages, reinforcing upward momentum. Notably, PLTR is well above its eight-day SMA (simple moving average) of $79.79, 20-day SMA of $74.48 and 50-day SMA of $73.06, all bullish indicators suggesting continued strength. 
The 200-day SMA at $42.02 further underscores a long-term uptrend, with the stock having nearly doubled over this period.
Momentum indicators also support the bullish case. The MACD (moving average convergence/divergence) indicator at 2.61 signals increasing upside momentum, often a precursor to further gains. However, the RSI (relative strength index) at 61.03 indicates that while the stock isn&#8217;t yet overbought, it is approaching elevated levels, suggesting some caution as PLTR stock nears resistance zones. 
PLTR stock investors should watch for potential consolidation or minor pullbacks, but the overall technical picture remains bullish.
<h2 class="wp-block-heading">&#8230;Yet Palantir Analysts See 9% Downside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/PLTR/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Palantir stock stands at a Neutral currently with a price target of $39.38. Recent analyst ratings from Wedbush, Cantor Fitzgerald and Morgan Stanley imply an 8.77% downside for PLTR stock, with an average price target of $74.
PLTR Stock Price Action: Palantir stock closed the trading day Friday at $82.49, up 1.56%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/43420511">Palantir CEO Alex Karp Sounds Alarm on China&#8217;s Deepseek – Could This Threaten Palantir&#8217;s AI Dominance?</a></li>
</ul>
Photo: Shutterstock

PLTR

Palantir Q4 Earnings Countdown: Bullish Charts Vs. Bearish Analysts

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) released its Q4 earnings on Monday, February 3, 2025 at 07:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Saia beat estimated earnings by 3.0%, reporting an EPS of $2.84 versus an estimate of $2.77.
Revenue was up $37.82 million from the same period last year.
<h3>Earnings History Overview</h3>
The company missed on EPS by $0.07 in the previous quarter, leading to a 11.0% increase share price change the next day.
Here's a look at Saia's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.53</td>
<td>4</td>
<td>3.44</td>
<td>3.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.46</td>
<td>3.83</td>
<td>3.38</td>
<td>3.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>839.88M</td>
<td>826.55M</td>
<td>770.66M</td>
<td>744.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>842.10M</td>
<td>823.24M</td>
<td>754.77M</td>
<td>751.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Saia <a href="https://www.benzinga.com/quote/SAIA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SAIA

Saia: Q4 Earnings Insights

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today reported preliminary selected unaudited results for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, revenue is expected to be approximately $27 million, reflecting a 17.8% increase compared to approximately $23 million expected to be reported for the fourth quarter of 2023 on a restated basis. For the full year 2024, revenue is projected to reach approximately $83 million, representing a 9.3% increase from $76 million in 2023. The Company expects to report that it had approximately $18 million in cash equivalents and investments and no long-term debt as of December 31, 2024.

Guidance

SWAG

SWAGW

Stran Announces Q4 2024 Revenue Of $27M, Up 17.8% From $23M In Q4 2023; FY24 Revenue Projected At $83M, A 9.3% Increase Over $76M In 2023; $18M In Cash and Investments, No Long-Term Debt As Of December 31, 2024.

TNYA

Tenaya Therapeutics Receives $8M Clinical Grant From California Institute For Regenerative Medicine; Funding will Support RIDGE-1 Clinical Trial Of TN-401 Gene Therapy

Mustang Bio (MBIO) was granted orphan designation from the FDA for a treatment of malignant glioma, according to a post to the agency's website. Pu...

Mustang Bio treatment of malignant glioma granted FDA orphan status

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Mustang Bio ( ($MBIO) ) has provided an announcement. Mustang Bio announced a significant agreement with an institutional investor for the exercise...

Mustang Bio Secures $4M through Strategic Warrant Agreement

Mustang Bio granted orphan drug designation by FDA for its malignant glioma treatment

Mustang Bio ( ($MBIO) ) just unveiled an update. Mustang Bio, Inc. faces potential delisting from Nasdaq as its stock price remains below $1.00 for...

Mustang Bio Faces Nasdaq Delisting and Leadership Changes

Mustang Bio files to sell 34.77M shares of common stock for holders

16:20 EST Mustang Bio (MBIO) files to sell common stock and warrants, no amount given Published first on TheFly – the ultimate source for real-time...

Mustang Bio files to sell common stock and warrants, no amount given

Mustang Bio files to sell common stock, warrants

19:50 EST Mustang Bio (MBIO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Mustang Bio trading halted, news pending

AKBA

ALLK

APVO

CNSP

CRMD

CYCC

DBVT

GNPX

IMUX

MBIO

ONCT

SGMO

SYRS

Financing

Press Releases

Mustang Bio Announces Closing of $4 Million Public Offering

Health Care

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Dividends

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Opinion

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Comments

Mustang Bio

Noticias

Últimas noticias sobre Mustang Bio (NASDAQ:MBIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL